Abstract Details

Title A Nationwide Analysis of Acute Ischemic Stroke in Intravascular Large B-Cell Lymphoma: The Needle in a Haystack

Topic Cerebrovascular Disease and Interventional Neurology

Presentation(s) P4 - Poster Session 4 (5:00 PM-6:00 PM)

Poster/Presentation
Number 13-009

Objective

To investigate the incidence of acute ischemic stroke (AIS) amongst patients diagnosed with intravascular large B-cell lymphoma (IVLBCL) and characterize predictors of stroke in this population. We also aim to explore outcomes of AIS patients with IVLBCL as compared to their counterparts without IVLBCL.

Background A significantly increased risk of cerebrovascular disease is well-documented in patients diagnosed with malignancy. VLBCL is a rare and aggressive subtype of non-Hodgkin B-cell lymphoma characterized by the proliferation of neoplastic lymphoma cells within the blood vessels of various organs. Literature regarding patients with IVLBCL and their stroke risk, has previously been limited to small single-center analyses.

Design/Methods The National Inpatient Sample (NIS) was queried from 2010 to 2019 using the International Classification of Diseases (ICD) 9^th and 10^th edition codes to identify patients admitted for AIS with and without IVLBCL.

Results We identified 44 IVLBCL cases amongst 705,928 AIS patients. We found that AIS patients with IVLBCL were older (74.50 vs 70.14 years, p<0.0001) and had less severe strokes (0.33 vs 0.47, p<0.01). They also had longer hospital stays (12.22 vs 5.99 days, p<0.01); however, they received similar rates of intravenous thrombolysis and mechanical thrombectomy and had similar rates of poor functional outcome and in-hospital mortality when compared to non-IVLBCL AIS patients. Multivariate regression identified age, hypertension, hyperlipidemia, congestive heart failure (CHF), and substance abuse as significant predictors of AIS in IVLBCL patients (OR > 1.0, p<0.05).

Conclusions Patients with AIS and IVLBCL are more likely to have favorable stroke severity rates despite their cancer diagnosis. Additionally, they had similar rates of reperfusion therapies as compared to AIS patients without IVLBCL, indicating their utility in this population. Similar to that of the general population, age, hypertension, hyperlipidemia, CHF, and substance abuse are important risk factors for AIS in patients with IVLBCL.

Authors/Disclosures
Brittany Russo, MD PRESENTER	Dr. Russo has nothing to disclose.
Adithya Nagaraja, DO	Dr. Nagaraja has nothing to disclose.
Ariel Sacknovitz, Medical Student	Mr. Sacknovitz has nothing to disclose.
Michael P. Fortunato, MD	Mr. Fortunato has nothing to disclose.
Martin Kafina, MD (Westchester Medical Center)	Dr. Kafina has nothing to disclose.
Ankita Jain, MS	Miss Jain has nothing to disclose.
Eris Spirollari, BA	Mr. Spirollari has nothing to disclose.
Anaz Uddin, MD	Dr. Uddin has nothing to disclose.
Esewi Aifuwa, Medical Student	Mr. Aifuwa has nothing to disclose.
Chaitanya Medicherla, MD	Dr. Medicherla has nothing to disclose.
Sarah C. Parauda, MD (Westchester Medical Center)	Dr. Parauda has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Panter, Panter & Sampedro.
Stephanie Gandelman, MD	Dr. Gandelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen. Dr. Gandelman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Amgen.
Fawaz Al-Mufti, MD (Westchester Medical Center at New York Medical College)	Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus. Dr. Al-Mufti has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Revalesio .

��ɫ��

��ɫ��